Fam-Trastuzumab Deruxtecan-Nxki

CHICAGO — Trastuzumab deruxtecan extended PFS compared with standard chemotherapy for certain patients with pretreated breast cancer, according to findings presented at ASCO Annual Meeting.

An analysis of global online conversations among health care professionals on social media in April revealed tremendous enthusiasm about FDA approval of a treatment for adults with advanced HER2-positive solid tumors.

Healio spoke with Paolo Tarantino, MD, about FDA approvals in metastatic breast cancer.

The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki for the treatment of adults with unresectable or metastatic HER2-positive solid tumors who received previous systemic therapy and lack additional treatment options.

An estimated 10% to 40% of patients with solid tumors develop brain metastases.

The FDA announced several regulatory actions the past few weeks.

Healio spoke with Sara M. Tolaney, MD, MPH, about the latest research in metastatic breast cancer.

Healio spoke with Sara M. Tolaney, MD, MPH, about recent advancements in metastatic breast cancer.

After decades of developmental challenges, antibody-drug conjugates have emerged as potentially less toxic and more effective treatment options for a variety of malignancies.

Healio spoke with Nancy U. Lin, MD, about metastatic breast cancer, touching on approvals, agents in the pipeline, surveillance, survivorship and other topics impacting clinicians and patients.